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Abstract
Background Incremental cost-effectiveness and cost-
utility analyses [health economic evaluations (HEEs)] of
vaccines are routinely considered in decision making on
immunization in various industrialized countries. While
guidelines advocating more standardization of such HEEs
(mainly for curative drugs) exist, several immunization-
specific aspects (e.g. indirect effects or discounting
approach) are still a subject of debate within the scientific
community.
Objective The objective of this study was to develop a
consensus framework for HEEs of vaccines to support the
development of national guidelines in Europe.
Methods A systematic literature review was conducted to
identify prevailing issues related to HEEs of vaccines.
Furthermore, European experts in the field of health eco-
nomics and immunization decision making were nomi-
nated and asked to select relevant aspects for discussion.
Based on this, a workshop was held with these experts.
Aspects on ‘mathematical modelling’, ‘health economics’
and ‘decision making’ were debated in group-work ses-
sions (GWS) to formulate recommendations and/or—if
applicable—to state ‘pros’ and ‘contras’.
Results A total of 13 different aspects were identified for
modelling and HEE: model selection, time horizon of
models, natural disease history, measures of vaccine-
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induced protection, duration of vaccine-induced protection,
indirect effects apart from herd protection, target popula-
tion, model calibration and validation, handling uncer-
tainty, discounting, health-related quality of life, cost
components, and perspectives. For decision making, there
were four aspects regarding the purpose and the integration
of HEEs of vaccines in decision making as well as the
variation of parameters within uncertainty analyses and the
reporting of results from HEEs. For each aspect, back-
ground information and an expert consensus were
formulated.
Conclusions There was consensus that when HEEs are
used to prioritize healthcare funding, this should be done in
a consistent way across all interventions, including vac-
cines. However, proper evaluation of vaccines implies
using tools that are not commonly used for therapeutic
drugs. Due to the complexity of and uncertainties around
vaccination, transparency in the documentation of HEEs
and during subsequent decision making is essential.
Key Points for Decision Makers
Health economic evaluations (HEEs) on vaccines
and vaccination programmes should always be
considered by decision-making bodies when
considering inclusion of a new vaccine into the
national programme to avoid suboptimal allocation
of resources.
Proper evaluation of vaccines implies using tools
that are not commonly used for therapeutic drugs in
HEEs. However, vaccines should only be treated
differently where they really are different (e.g.
indirect effects).
Funders and decision-makers should recognize that
proper and valid HEEs (of vaccines) demand time
and resources.
1 Introduction
Health economic evaluations (HEEs) are widely used to
evaluate new health technologies, and several guidelines of
the World Health Organization (WHO) and other authori-
ties exist and provide guidance on how to properly conduct
such analyses [1–8]. Furthermore, many national immu-
nization technical advisory groups (NITAGs) and/or
respective national institutions in high-income countries
routinely consider results from HEEs for the evaluation of
vaccines (Fig. 1 [9–14]). However, comprehensive guide-
lines or frameworks on (1) how to best conduct HEEs of
vaccines and (2) how to implement their findings into
immunization decision making are scarce. Members of a
European vaccine economics community developed a
framework on how to deal with several relevant aspects in
the field of HEEs of vaccines. The aim of this paper was to
provide a consensus framework on how to apply HEEs to
vaccines and to identify areas where further work is needed
to reach harmonization. In this paper, we focused on vac-
cines for the prevention of infectious diseases, on aspects
relevant to high-income countries, and on incremental cost-
effectiveness and cost-utility analyses that serve as refer-
ence case in most European healthcare reimbursement
systems.
2 Methods
Experts (authors of this manuscript) with expertise in
mathematical modelling, health economics and/or immu-
nization decision making from Europe were invited by the
Robert Koch Institute (RKI, Germany) to develop a
framework on methods for HEE of vaccines and immu-
nization decision making. European experts from acade-
mia, national public health or health technology assessment
bodies as well as from relevant national and international
health authorities were selected by following criteria: (1)
authorship of key publications and/or (2) (former)
Fig. 1 Map of Europe indicating whether results from economic
evaluations of vaccines are routinely considered in recommendations,
based on [9, 11–14] (asterisk no response from country, country not
considered, Malta and Cypress not shown)
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membership of a NITAG and/or (3) (former) employee of a
(inter-) national decision-making body and/or (4) (former)
employee of a health technology assessment body. To
minimize potential and perceived conflicts of interest,
experts employed by a pharmaceutical company were not
invited to this meeting. However, since several of the
invited experts had experience in conducting HEEs com-
missioned by industry or interacting with industry, e.g.
during scientific debates, a comprehensive view on relevant
aspects was ensured.
2.1 Systematic Literature Review and Preparation
of a Workshop
After obtaining feedback from the expert group, a sys-
tematic literature review on methodologies and guidelines
related to HEEs of vaccines was conducted. The databases
MEDLINE and EMBASE were searched with a time
horizon from 1 January 1990 to 21 February 2014 targeting
five topics: ‘Vaccines and infectious diseases’, ‘economic
evaluation’, ‘guidelines’, ‘methods’ and ‘decision making’.
Search terms identified in study title and/or abstract within
each topic were connected with an ‘OR’ (see Table 1).
Three search branches were developed. In each search,
branch topics, ‘Vaccines and infectious diseases’ and
‘economic evaluation’ were connected with an ‘AND’ and
further connected (‘AND’) with the following:
• ‘Guidelines’ (search branch 1) OR
• ‘Methods’ (search branch 2) OR
• ‘Decision making’ (search branch 3).
Studies were excluded on the following criteria:
• they did not have a methodological purpose, or
• they did not have a vaccine context, or
• they considered exclusively non-industrialized
countries.
Titles and abstracts of studies were screened indepen-
dently by two reviewers. Potentially relevant studies were
retrieved and assessed according to the three exclusion
criteria by reviewers. Disagreements between both
reviewers on exclusion of particular studies were resolved
by consensus. Search branches 1 and 2 were further com-
bined with an AND. Additionally, studies found by hand
search (e.g. by the ‘snowballing technique’) were included.
Finally, the identified literature was analysed for prevailing
opinions and/or remaining questions.
Based on the included studies, pertinent aspects were
identified and experts were asked to select the most relevant
aspects in which currently required forms of HEE [mainly
incremental cost-effectiveness ratio (ICER) calculations] of
vaccines preventing infectious diseases differ from HEE of
curative drugs. According to the experts’ feedback, aspects
were selected for discussion in a 2-day workshop. With this
approach of combining systematic reviews and subsequent
expert consultation, a coverage of most relevant aspects was
achieved, including differences between HEE of curative
drugs and HEE of preventive vaccines.
2.2 Conduct of a Workshop
After an introduction and key note lectures, aspects in the
area of (1) modelling methods, (2) health economics, and
(3) decision making were discussed in group-work sessions
(GWS). Findings from the literature review were used to
guide discussions during GWS. Based on a workshop
reader (available online [15]) the groups on ‘modelling
methods’ and ‘health economics’ were asked to provide—
where possible—concrete ‘recommendations/suggestions’
for use of a specific item per aspect and/or were asked—if
applicable—to list ‘pros and contras’ as well as ‘future
challenges’ of certain items within an aspect. For the ‘de-
cision making’ GWS, a more explorative approach was
chosen. Findings from GWS were then presented and dis-
cussed in plenary. Besides the identification of relevant
aspects and remaining issues, the experts were asked to
formulate consensus on how to handle certain aspects.
Consensuses and compromises were achieved through
expert discussions and voting. Where no consensus could
be achieved, experts were asked to present different options
or points of view.
3 Results
3.1 Identified Studies
The flow chart in Fig. 2 describes the identification process
of the relevant studies. Search branch ‘methods’ (branch 1
and 2) resulted in the identification of 42 [16–57] studies.
Search branch ‘decision making’ (branch 3) identified 26
studies [9, 21, 44, 58–80].
3.2 Identified Aspects for Discussion
Based on the identified studies and experts’ feedback, 17
aspects were selected for discussion in the workshop. The
results of expert discussion on each aspect are presented in
Sects. 3.3.1–3.3.13 and 3.4.1–3.4.4.
3.3 Modelling Methods and Health Economics
3.3.1 Model Choice
Background [17, 18, 20, 22–25, 27, 28, 30, 32, 34, 37, 42,
44, 46, 47, 54]:
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There are several types of models:
i. Static cohort models;
1. Decision tree,
2. Markov model.
ii. Population models;
a. Static model,
b. Dynamic model:
1. Compartmental transmission dynamic models,
2. Agent-based models,
3. Discrete-event models.
Models from the category (ii-b) can intrinsically account
for transmission of pathogens between individuals or
population fractions that influence diseases transmission by
indirect effects—dynamic models. Models from categories
(i) and most of (ii) are often of a deterministic nature. Input
parameters are set deterministically, and base-case results
and uncertainty analyses are fully replicable. Models from
category (ii-b-2 and ii-b-3) usually use a stochastic
approach. For example, a study from Spain analysed the
health economic effects of a seasonal influenza vaccination
by using both a static and a dynamic model approach [46].
In contrast to the dynamic model’s results, the static model,
neglecting indirect effects (such as herd protection), could
not show that the influenza vaccination is cost saving.
Hence, using a static model might underestimate a vac-
cine’s value [46].
Table 1 Systematic literature research
Topics Vaccines and infectious
diseases
Economic evaluation Guidelines Methods Decision making
Search
terms (in
Title OR
Abstract)
Vaccine OR
Vaccination OR
Vaccinate OR
Vaccinating OR
Vaccinated OR
Immunization OR
Immunisation OR
Immunize OR
Immunise OR
Infectious disease OR
Communicable
disease OR
Preventable disease
Cost OR Cost
effectiveness OR
Cost utility OR Cost
benefit OR Benefit
cost OR Cost saving
OR Economic OR
Pharmacoeconomic
OR
Pharmacoeconomics
OR Budget impact
OR Efficiency OR
Efficient OR
Monetary OR
Financial OR ICER
OR QALY
Guideline OR Guide
OR Good-practice
OR Good OR practice
OR Good research
practice OR
Standards OR
Standard OR
Recommendation OR
Recommendations
OR Framework OR
Frameworks OR
Primer OR Consensus
Methoda OR Methodsa
OR Methodological
OR Decision analytic
OR Decision analysis
OR Decision analyses
OR Modela OR
Modelsa OR
Modellinga OR
Modelinga OR Model
based OR Simulation
OR Simulation OR
Mathematical OR
Transmission OR
Dynamic OR
Discounting OR
Interaction OR Herd
immunity OR Herd
protection OR Herd
effects OR Indirect
effects OR
Population-wide
benefits OR Waning
Decision making OR
Reimbursement OR
Fourth hurdle OR
Payer OR Pricing OR
Funding OR
Willingness to pay
OR Threshold OR
Value for money OR
Social value OR
Social preferences
OR Public health
Search
branch 1
• AND • AND •
Search
branch 2
• AND • AND •
Search
branch
‘methods’
(1 ? 2)
• AND • AND • AND •
Search
branch
‘decision
making’
(3)
• AND • AND •
a Searched in title only
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Expert consensus:
• For infectious disease modelling, the sole use of static
models should always be justified. Static models can
be used as a conservative estimate when there is no
evidence for harm (e.g. age shifts with adverse effects)
if indirect effects are ignored [4, 30, 34, 81, 82].
WHO has developed a flow chart that provides
assistance when choosing an adequate type of model
(Fig. 3) [4].
• A challenge is to handle realistic demographic predic-
tions in models (with a long time horizon) because of
migration, demographic changes and scarcity of contact
studies in (special) populations.
• Stochastic models;
Advantages:
• Simulate a more realistic world.
• Can follow an individual’s life course, which is easier
for decision-makers to understand.
• In stochastic models, the randomness is of first-order
uncertainty; therefore, they provide an alternative
to account for heterogeneity (if events are not rare)
in subgroups as it is done in a deterministic
model [81].
Disadvantages:
• Model calibration and the probabilistic sensitivity
analysis (PSA) become more challenging and compu-
tationally intensive, hence, transparency might suffer.
• Data sources may not be accessible, as more fine-
grained (non-aggregated) data are needed.
• A remaining challenge is to find adequate ways to
conduct efficient uncertainty analyses on stochastic
models [83].
3.3.2 Time Horizon of Models
Background [18, 27, 34, 37]:
Outcomes of static cohort models are typically estimated
over a single cohort’s lifetime or a specific time horizon in
which the disease typically occurs that is set as the time
horizon of the model. In dynamic population-based
Fig. 2 Flow chart of the systematic literature review
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models, the entire population is modelled, and the time
horizon of those models has three phases:
1. Run-in phase Dynamic models need a run-in phase to
model the epidemiological conditions in the pre-
vaccination era. This is important for a realistic
implementation of the respective vaccination. The
duration of the run-in phase impacts the model’s
results.
2. Evaluation phase This phase starts with the imple-
mentation of the vaccination. The duration of the phase
should be set in the model as long as necessary to
Vaccination in 
humans
Infectious disease 
(at equilibrium)
Non-infectious 
disease
Human to human 
transmission 
non-existent
Human to human 
transmission common
Static 
model
Vaccine reduces susceptibility 
to infection and/or infective 
transmission potential
Vaccine does not reduce
susceptibility to infection or 
infective transmission potential
Static 
model
Static model shows 
favorable results for 
vaccination
Static model including observations 
on externalities from a comparable 
setting acceptable
Static 
model
Static model shows unfavorable 
or borderline favorable result for 
vaccination
One of the eligible target groups is 
or includes an epidemiologically
influential subgroup
The eligible target groups are not or
do not include an epidemiologically
influential subgroup
There are no negative externalities from
vaccination, or these are very likely to be
smaller than positive externalities
There are negative externalities from
vaccination, which potentially 
exceed positive externalities
Static 
model
Dynamic 
model
Dynamic 
model
Dynamic 
model
Static 
model 
acceptable
Fig. 3 Flow chart for model
choice adopted from the World
Health Organization [4]
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cover indirect (positive or negative) effects caused by
the vaccination in the population.
3. Steady-state After a certain duration of the evaluation,
an epidemiological equilibrium is reached—the steady
state—where the epidemiological variation terminates.
Combining model choice with time horizon, Mauskopf
et al. [37] identified four categories of evaluation strategies
(see Table 2). For example, a cost-effectiveness analysis of
human papillomavirus (HPV) vaccination for Austria
showed in sensitivity analyses that an extension of the
model’s time horizon by almost three decades decreased
the ICER from €50,000/life-years gained to\€0/life-years
gained [84].
Expert consensus:
• The time horizon of a dynamic model should last until
the steady state is achieved in order to deliver valuable
results. Hence, the model’s time horizon should not be
defined prior to the analysis.
• Dynamic population models should be evaluated by
category 1 (Table 2). ICERs should be projected over
time until their cumulative value stabilizes. However, if
this takes more than two decades, cumulative ICERs
should be presented for different time horizons (e.g.
Kim and Goldie [34]).
• Future research must analyse the impact of these
different strategies.
• A model usually should be run to epidemiological
equilibrium, but it ideally should reproduce historical
epidemiological (and demographic) values that may not
be in equilibrium. There is a need for validation of pre-
vaccination as well as post-vaccination epidemiology
(whatever is available/applicable). However, this is
often technically challenging and may suffer from lack
of data.
• A surveillance system should be implemented to
monitor the impact of a vaccination programme. The
results can be used to compare the real impact with the
impact predicted in the model that was developed
before the vaccine was implemented and to evaluate the
model.
3.3.3 Natural History of Disease
Background [30, 52]:
Pathogen-specific naturally acquired immunity (includ-
ing its waning) is usually an important feature in dynamic
models. The way this is modelled has an influence on the
results [exemplary model structures: ‘susceptible-infec-
tious-susceptible’ (SIS), ‘susceptible-infectious-recovered’
(SIR), ‘susceptible-infectious-recovered-susceptible’
(SIRS), ‘susceptible-exposed-infectious-recovered-suscep-
tible’ (SEIRS)]. In principle, the structure of a model
should be developed on the base of the characteristics of
the specific target disease, the vaccine of interest and the
respective research question. However, for the same vac-
cine-preventable disease different compartment structures
have been used in published studies. For example, a study
analysing the health economic effects of seasonal influenza
vaccination in Spain used an SIR approach, whereas a
study considering the same disease in England used an
SEIR structure [46, 85]. Particularly in health economic
models for HPV vaccination, the use of an SIR and the use
of an SIS structure are common, and the use of both
structures can be justified [52, 86].
Expert consensus:
• The model’s structure should represent the state of
knowledge on the specific disease.
• If uncertainty exists, structural uncertainty analysis
should be performed [40, 87].
• Better (sero-) epidemiological and immunological data
are needed to inform such models.
3.3.4 Measures of Vaccine-Induced Protection
Background [16, 29, 42, 45, 54]:
Different vaccine efficacy (VE) measures can be con-
sidered in HEEs to account for protection against different
outcomes such as infection, symptomatic illness/compli-
cation, and/or infectiousness.
If an infection does not cause any symptoms at all at any
stage, and thereby does not require treatment and/or
Table 2 Evaluation strategies of health economic models [37]
Evaluation strategy Target population Time horizon Start of evaluation
Category 1 Entire population Fixed TH (several years or decades) From implementation of vaccination
Category 2 Entire population 1 year From steady state
Category 3 Cohorta Cohort’s lifetime or fixed TH From implementation of vaccination
Category 4 Cohorta Cohort’s lifetime or fixed TH From steady state
TH time horizon
a One or more cohorts
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prophylaxis costs, there is no need to consider this in an
economic assessment. For example, based on data from
influenza challenge studies, Basta et al. [16] estimated
absolute VEs for different endpoints. For example, vaccine
efficacy for seasonal live-attenuated influenza vaccines in
homologous seasons ranged between 40 and 90 % (VE for
susceptibility 40 %; VE for infectiousness 50 %; VE for
illness given infection 83 %; VE for infection-confirmed
influenza illness 90 %).
When developing a model, the hierarchy of disease
states/endpoints must be incorporated to consider the rel-
evant type of VE.
• There is a ‘sequential’ [targeting the first endpoint only,
e.g. VE protecting against herpes zoster (HZ) only]
• A ‘non-sequential’ [targeting all VE-relevant endpoints
independently, e.g. VE protecting against HZ and also
against HZ complication post-herpetic neuralgia
(PHN)] approach
A study evaluating the cost effectiveness of a vaccine
preventing HZ in the USA used, for instance, a sequential
approach [88]. Hence, only VE against HZ was considered,
and VE against the complication PHN was neglected.
However, this approach was criticized by Brisson and
colleagues [89, 90], who used a non-sequential approach
when evaluating the cost effectiveness of an HZ vaccine in
Canada. In this study, the model was informed with both
VE against HZ and VE against PHN, and delivered results
more in favour for the vaccine [90].
In clinical trials, two different approaches of analysis are
often used to measure VE:
• per protocol (PP) and
• intention to treat (ITT).
PP usually produces more favourable VE results for the
intervention/vaccine than ITT.
Furthermore, in models, the degree of protection and
take can be distinguished.
• The degree of protection (or leaky protection) is the
percentage of (partial) protection in successfully vac-
cinated individuals (e.g. 100 % of vaccinated individ-
uals have a protection of 50 %).
• Take (or ‘all or nothing’) describes the percentage of
successfully vaccinated individuals with full protection
(e.g. 50 % of vaccinated individuals have a protection
of 100 %).
A mathematical model, for instance, calculated the
impacts of fictional HIV vaccines on seroprevalence,
depending on whether the vaccine leads to a take or a
degree protection. The seroprevalence proportion was,
after several decades, lower when using a take protection
than a degree protection [91]. This difference can impact
the overall results of a health economic model [92].
Finally, a major challenge is a lack of clinical endpoints
in clinical trials, especially when immunogenicity (or other
surrogate of protection) is the outcome considered for
licensure. The preferences, whether to use efficacy or
effectiveness data in HEEs, are rather diverse in European
guidelines [14].
Expert consensus:
• The model structure should account for the type of VE
measure incorporated. VE in terms of reducing sus-
ceptibility to infection is fundamentally different to VE
reducing infectiousness. These different aspects of VE
have a differential impact on the results. Modelling can
be used to estimate unknown parameters including VE
estimates by using, for example, a Bayesian framework
utilizing Markov Chain Monte Carlo inference [93].
More studies assessing VE against infectiousness are
warranted (e.g. challenge studies).
• Model structure and the decision-maker’s research
question determine the use of a sequential or non-
sequential approach.
• ITT data, when available, should be taken for base-case
analyses and PP data for uncertainty analyses. How-
ever, the use of PP data for the base-case is sufficient
when the difference between ITT and PP data is
completely explained by the different proportions of
susceptible individuals in the study population, since
this is ideally incorporated in a model. PP data should
be preferably chosen if a specific result on vaccine-dose
compliance and/or completion of a vaccine course is of
relevance.
• The choice of representing VE with degree of protec-
tion versus take depends on the type of protection
conferred by the vaccine of interest. When there is no
evidence on whether the vaccine confers a leaky or an
all-or-nothing protection, different approaches to
account for vaccine efficacy (leaky or all-or-nothing
or combination) should be used.
• The quantitative relationship between immune response
and the degree of vaccine-induced protection against
clinical disease is often unclear. Validated surrogates
can be considered if no clinical endpoints are available.
• The impact of negative vaccine effects, both at an
individual level (i.e. adverse events) and at a population
level (i.e. replacement or age shift) needs to be
considered. Cases of vaccine-preventable diseases and
cases of adverse events are equally relevant outcomes.
• Vaccine manufacturers currently have little incentive to
collect some specific clinical data (e.g. head-to-head
comparisons of different vaccine products); however,
these are relevant for modelling and public health. For
234 B. Ultsch et al.
comparison of different studies, standardized case
definitions for clinical outcomes are needed, and
methods for the implementation of such indirect
comparisons into models should be
developed/standardized.
3.3.5 Duration of Vaccine-Induced Protection
Background [30, 52]:
The waning of vaccine-induced protection plays a major
role when modelling vaccine effects. Clinical trials are
often too short to generate robust data on the duration of
vaccine protection. In a model, either a lifetime duration
(neglecting waning) is assumed or waning is incorporated.
Waning can be designed to start right after vaccination or
after a delay period, and to decay in different ways (e.g.
exponential, stepwise). With the example of HZ vaccina-
tion, it can be shown that different assumptions on the VE
waning rate can impact the health economic results: in a
study from Germany, vaccination at the age of 60 years
resulted in an ICER of €21,565/quality-adjusted life-year
(QALY) gained or €34,606/QALY gained assuming an
annual waning rate of 1 or 20 %, respectively [94]. In this
model, when vaccinating individuals at the age of 50 years,
the same waning rates led to €18,486 and €43,701/QALY
gained, respectively. Especially in health economic models
on HPV vaccination, the waning of vaccine-induced pro-
tection is an influential determinant of overall results [52,
86, 95].
Expert consensus:
• If vaccine waning is not well understood, then different
waning scenarios should be considered in an uncer-
tainty analysis and their impact compared. Immuno-
logical memory can be integrated.
• The availability of detailed trial data on vaccine-
induced protection and waning at the patient level
would enable more rapid and less uncertain economic
evaluations following the marketing of a new vaccine.
3.3.6 Indirect Effects Apart from Herd Protection
Background [18, 20, 27, 30, 37]:
Vaccination-specific negative externalities such as age
shift of peak incidence, serotype replacement or impact on
antibiotic resistance might be relevant. The cost effec-
tiveness of pneumococcal vaccination, for example, is
strongly influenced by the degree of serotype replacement
that is expected after vaccine introduction. This influence
was shown by van Hoek et al. [96] in a study on the cost
effectiveness of a 13-valent pneumococcal conjugate vac-
cination for infants in England. Brisson and Edmunds [97,
98] illustrated that the routine infant vaccination against
varicella is expected to increase the average age at infec-
tion. This age shift is caused by two effects: the cohort
effect and the herd protection effect. If the disease severity
increases with age at infection, this age shift negatively
impacts the overall health-economic results.
Expert consensus:
• Ecological effects such as intra-population immune
boosting following exposure to a pathogen (cf. vari-
cella-zoster virus), replacement of pathogen strains
covered by a vaccine by strains not covered (e.g.
pneumococcal serotypes) and antibiotic resistance
should be part of uncertainty analyses whenever they
are possibilities.
• Ideally, pathogen replacement, eradication, genetic
selection in host, changes in behaviour (e.g. screening
uptake, risk behaviour such as unprotected sex or social
mixing), weakening of maternal immunity, and using
vaccination as a platform for adding other interventions
should also be considered wherever relevant.
3.3.7 Target Population
Background [20, 23, 29, 30, 42, 43]:
Besides the question of whom to vaccinate (e.g. total
population at a certain age versus risk groups) it is neces-
sary to consider how populations/groups mix with each
other. In dynamic models, contact patterns and the mixing
matrix influence the model outcome. The literature offers
data gathered by different approaches, e.g. survey-based
(e.g. POLYMOD) and synthetic (social demographic data)
contact matrices. For example, to understand contact pat-
terns of infants, a study group sent contact diaries to a
representative sample of mothers in the UK. Thereby, the
average number, the type, and the duration of daily con-
tacts of infants were documented. These data can serve as
important input parameters for dynamic models evaluating
the impact of vaccines [99]. Since observational data on
contact patterns in the form of age-specific contact matrices
are difficult to gather and are currently available only for
few countries, Fumanelli et al. [100] presented a compu-
tational approach. Based on the simulation of a virtual
society of agents based on data collected in eight European
countries, contact patterns by age can be estimated for 26
European countries. This approach might serve as a valu-
able alternative to observational data [100]. Such synthetic
contact matrices have been used by Poletti et al. [101] in a
varicella-zoster virus study.
Expert consensus:
• Survey-based mixing data are considered most ade-
quate and should be used wherever possible. Synthetic
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methods need to be validated against survey data where
available.
• Future research should better measure contact patterns
for children and parents, and evaluate what kind of
contact is relevant. Knowledge is still lacking about
how well contact patterns represent occasions for
transmission for specific infections. It is therefore
important to assess which subset of mixing data (e.g.
contacts involving touching) provides the best fit to
relevant observational data for the disease in question
(e.g. seroprevalence data). Research funders need to
understand that contact matrices are important for
dynamic model projections, and that these differ
between countries or regions.
3.3.8 Model Calibration and Validation
Background [18, 23, 34, 40, 42, 50, 51, 53, 55]:
Calibration means estimating and adjusting a model’s
parameters to generate the expected outcomes observed in
real life. The literature reports several approaches such as
manual, random (e.g. Monte Carlo) or optimized (e.g.
Nelder-Mead [102]) approaches. External validation com-
pares the results of the model with the best available evi-
dence. For example, Kim et al. [103] present calibration
methods on how to use real-world data to develop a
comprehensive natural history model of HPV. Hence, a
calibrated model that fits to real-world data tends to gen-
erate more reliable results [103]. However, Basu and
Galvani [104] claim that a Bayesian approach provides
several advantages compared with the approaches pre-
sented by Kim et al. [103].
Expert consensus:
• The manual calibration approach should be based on a
structured process, and the algorithm should be
reported. However, the random or optimized approach
is considered to be more adequate [53, 105–107]. A
random calibration approach may have an identifiabil-
ity issue. Hence, researchers should make sure that the
shape and range of the posterior distribution is
plausible.
• A plain visual validation is not considered sufficient.
Instead, the use of goodness-of-fit criteria is
recommended.
• The dataset used for validation should be independent
from that used for calibration (ideally even with
different endpoints). An alternative is to hold back a
portion of the calibration data (e.g. test/training
datasets). An alternative option is a cross-model
validation approach in which the same data are used
on different models. Lack of data points might be a
limitation.
3.3.9 Handling Uncertainty
Background [18, 22, 26, 30, 34, 37, 42, 45, 48, 54]:
Structural (or model) uncertainty can be handled by sce-
nario analysis (i.e. presenting results for different models),
model averaging or parameterizing the structural uncertainty
[108–110]. Parameter uncertainty is quantified with PSA.
However, PSAs are often not performed in dynamic models
because they are computationally difficult (especially to
include the uncertainty of parameters affecting transmis-
sion). Alternatively, parameters affecting transmission are
excluded from PSA, or two models are developed: an eco-
nomic sub-model including PSA and a dynamic sub-model
focusing on transmission-specific issues. Furthermore, there
are many vaccination-specific key aspects for uncertainty
analysis, such as duration of vaccine protection, vaccination
coverage in dynamicmodels, time horizon, boosting, contact
patterns and targeted age/risk groups. For example, to con-
sider both indirect effects caused by vaccination and PSA,
Christensen et al. [111] developed two models (static and
dynamic) to evaluate the potential impact of introducing
vaccination against serogroup B meningococcal disease in
the UK. The static model without parameters affecting the
transmission was used to perform PSAs. The dynamicmodel
including parameters affecting the transmission was used to
account for indirect effects [111].
Expert consensus:
• All identifiable sources of uncertainty should be
accounted for, if not by PSA then by other analyses.
The parameter distributions used in PSA need to be
justified. Transparency is important because dynamic
models can have many ‘deep parameters’ (i.e. param-
eters that are not directly observable, such as the
probability of infection transmission per contact event).
Calibrated parameters also need to capture information
about uncertainty [87, 112].
• Decision-makers need to understand the relevance of
uncertainty analyses. PSA can help to identify future
research priorities. However, uncertainty measures in
calibrated parameters remain challenging.
• Structural uncertainty should be parameterized where
possible, but uncertainty in normative aspects such as
perspective, vaccine price and discounting should not
be analysed in PSA [87, 112]. Vaccine coverage should
be varied between desirable and undesirable levels.
Uncertainty in contact patterns should be parameterized
wherever possible (see Table 3).
3.3.10 Discounting
Background [1, 18, 19, 25, 35, 38, 39, 41, 42, 44, 45, 49,
54, 56, 57, 113]:
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Uniform discounting (using the same rates for costs and
health effects) is most commonly applied in HEEs. How-
ever, this approach might considerably influence the long-
term ICERs of vaccination in particular, since costs and
benefits usually occur at different points of time. Differ-
ential discounting (with lower rates for health effects) is
used, for example, in Belgium, the Netherlands, Poland
and, until 2004, the UK, for the assessment of all health
technologies, including vaccines. Differential discounting
seems to be technically feasible and fairer from an ‘inter-
generational’ perspective [114]. Different recommenda-
tions on discounting approaches, for example, drugs and
vaccines within one country, do not exist. If lower discount
rates for health effects are considered, the level of discount
rate for health effects needs to be set separately. Another
issue in this context is whether a constant or a changing
discount rate over time is used. Constant rates are more
widely used, possibly because of pragmatism and ease. In
France, the first 30 years are discounted with a uniform rate
of 4 %, and years thereafter at 2 %. This ‘slow’ dis-
counting procedure is also recommended by WHO if the
effects of vaccination begin only long after the intervention
(e.g. vaccination against HPV) [4]. The type of decline can
vary (e.g. stepwise, linear, or exponential). For example,
Westra et al. [57] used nine different discounting approa-
ches and rates in a model evaluating the cost effectiveness
of the HPV vaccination in the Netherlands. Ceteris paribus,
the ICERs ranged between €7,600/QALY gained and
€165,400/QALY gained.
Expert opinion1:
• The majority of, but not all, experts recommended
differential discount rates for costs and effects in HHEs
(exclusively in cost-utility and cost-effectiveness
analysis) if the model’s time horizon is long (e.g.
[20 years).
• The discount rate of health effects could be around
50 % of the discount rate for costs. However, for a
more evidence-based recommendation, empirical
research has to be conducted [39].
• Constant discount rates over time should not be applied
in models with a long time horizon (e.g. [20 years)
according to a majority of experts.
• Further research on the, to date rarely applied, approach
called time-shifted discounting approach is needed [39,
57, 115].
• Since discount rates and discount approaches usually
have a major impact on results of HEE of vaccines, the
variation of these aspects need to be analysed (see Sect.
3.3.9) and explained to decision-makers.
3.3.11 Health-Related Quality of Life and Quality-
Adjusted Life-Years as Outcome Measures
Background [20, 25, 32]:
QALYs are a common outcome measure used in cost-
utility analyses and are accepted in several countries in
Europe [14]. Since vaccine-preventable diseases often
affect children, the impact on health-related quality of life
(HR-QOL) of carers measured as QALYs is important in
HEEs of vaccines. Another prevention-specific issue is
utility in anticipation, measured as QALYs. Vaccinated
individuals might experience a higher HR-QOL, because
they feel ‘protected’ after vaccination. As counterpart, fear
of adverse events measured as QALYs also needs to be
mentioned. That might lead to an HR-QOL decrease, but
on a rather short time horizon. For example, Weinke et al.
[116] used a survey to assess the impact of HZ and PHN on
the patients’ life but also on life of the family members
who cared for them. Most family members (69 % children;
Table 3 Definition of uncertainty analyses based on expert consensus and literature [22, 30, 42, 55, 87, 112]
Type of uncertainty Sensitivity analysis Scenario analysis
Parameter
uncertainty
Methodological/normative uncertainty Structural/model uncertainty
Deterministic sensitivity
analysis
Yes Yes Yes Yes
PSA Yes NA NA NA
Examples • Efficacy
• Costs
• Transmission dynamic vs. discrete-
event simulations
• Discount rate
• Presence of a immune state (SIS
vs. SIR)
• Pathogen strain competition and
replacement
• Coverage
• Target age/risk
group
• Vaccine price
NA not applicable, PSA probabilistic sensitivity analysis, SIR susceptible-infectious-recovered, SIS susceptible-infectious-susceptible
1 Since an expert consensus was not reached, we used the term
‘expert opinion’.
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80 % life partners) of patients with HZ or PHN reported
that caring for the patient caused a moderate to severe
impact on their life. Hence, these impacts might have an
effect on overall health economics results [116].
Expert consensus:
• HR-QOL of carers should routinely be considered in
uncertainty analysis in both payers’ and societal
perspectives. However, input data might be scarce.
• Utility in anticipation and fear of adverse events are
also difficult to consider due to limited data. When
appropriate data are available, they might be considered
in uncertainty analyses.
3.3.12 Cost Components
Background [18, 32, 36]:
Even though the literature and national guidelines on
(direct or indirect) cost components seem very compre-
hensive, some factors are vaccine specific and require
attention. Traditionally, vaccines mainly protect against
diseases occurring in childhood. Since sick children need
care, indirect costs of carers (e.g. productivity loss) occur.
Set-up costs (e.g. of vaccine campaigns) might also play an
important role in immunization programmes. Depending
on the disease and the target group, campaigns are needed
to reach as many individuals as possible. Respective
national guidelines often neglect such cost components.
For example, in the model by Hornberger and Robertus
[117], that evaluated the cost effectiveness of HZ vacci-
nation in the USA, the price for the vaccine included the
unit vaccine cost, a public awareness campaign, adminis-
tration costs, patient travel time and time receiving vaccine
as well as the cost of treating adverse events. Implementing
$US500 per vaccine dose caused high ICERs of between
$US280,000 and $US560,000/QALY gained [117].
Expert consensus:
• Indirect costs of carers should be considered for both
perspectives. From a payers’ perspective, they are
considered as sick pay (if the payer has to cover these
costs) and from a societal perspective as productivity
loss.
• If set-up costs (e.g. for campaigns) are not included in
the vaccine price (i.e. promotion and distribution of a
vaccine is not done by its manufacturer), they should be
considered in the perspective that covers these costs.
3.3.13 Perspectives
Background [18–20, 32, 54]:
Some prevailing methodological primers recommend
using the societal perspective when assessing vaccination
programmes designed to improve public health. A recent
systematic literature review on varicella and HZ vaccina-
tion concluded that the varicella vaccination (neglecting
the impact on HZ) becomes cost saving when switching
from a payer to a societal perspective [118]. Hence, indi-
rect costs especially of carers when considering infant
vaccination, tend to have a major impact on overall health
economic results [118]. However, for example, if costs for
vaccination are higher from a societal perspective due to
co-payments, the overall results from the societal per-
spective can become less cost effective when compared
with those from the payer perspective [119, 120].
Expert consensus:
• A societal perspective should ideally be taken for the
base-case analysis when considering infectious diseases
(i.e. not for vaccines exclusively), unless this contra-
dicts national guidelines.
3.4 Decision Making
Background [9, 24, 41, 58–70, 72–79]:
3.4.1 Purposes of Health Economic Evaluations
in Decision Making
From the decision-makers’ perspective, results from HEE
of vaccines can be utilized to identify the most efficient
vaccination strategies (e.g. targeting the total population or
specific age or risk groups—technical efficiency), to sup-
port yes/no decisions for vaccine introduction, and/or to
support price negotiations with manufacturers (allocative
efficiency). Furthermore, the introduction of a new vaccine
usually substitutes for curative treatment and/or screening
measures in a healthcare system. Those substitutions are
also of relevance for decision-makers and are usually
considered in HEEs. Furthermore, the experts clearly stated
that additional budget impact analyses (BIA) can be useful,
especially when a costs of a prevention/intervention mea-
sure is extremely high and affordability is unclear.
3.4.2 Integration of Health Economic Results in Decision-
Making Processes
The introduction of a new vaccine into a healthcare system
affects several aspects of the system. Hence, many ques-
tions, such as acceptance, practicability or equity in access,
must be addressed. Erickson et al. [62] provide a com-
prehensive view on all factors that could be considered in
immunization decision making. A broad micro- and macro-
economic view might be useful. Many but not all questions
can be addressed within a health economic model, but
should also be considered within a broader appraisal.
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However, details of a broader appraisal were not subject to
this framework. Furthermore, other health economic
approaches, such as cost-benefit analyses or BIAs, may
also serve as a basis for decision making. However, which
or how many approach(es) are considered for decision
making is a rather normative question that needs to be
address by relevant stakeholders at the national level.
Therefore, experts concentrated in this framework on
incremental cost-effectiveness and cost-utility analyses,
that are the most commonly used forms of HEEs for
national decision making in Europe [14]. Yet, the experts
acknowledged the usefulness of broader and alternate
approaches in the economic analysis of vaccines.
In general, the experts cautioned that lack of trans-
parency and high complexity of evaluations leads to results
from HEEs appearing like a black box to decision-makers.
Based on a decision making continuum, experts stated pros
and contras of three decision making approaches: pure
threshold, multi-criteria decision analysis (MCDA), and
informal judgment (Fig. 4). Decision making based on a
pure threshold is transparent. Especially if the budget is
very constrained, a fair use of public resources is possible
and it is a useful tool for price negotiations with manu-
facturers. However, pure threshold does not consider
clinical/epidemiological severity or budget impact. Fur-
thermore, the choice of the level or range of the threshold
sometimes seems rather arbitrary, and in some countries
such willingness-to-pay thresholds are not accepted.
MCDA is also transparent and applicable without a
threshold. However, MCDA is very complex, needs a well-
developed design and requires proportional weights of each
criterion. Clearly, in terms of MCDA, more research is
needed. In terms of informal judgment, experts recognized
advantages such as applicability without a threshold and
comprehensive summary of many parameters related to the
respective vaccine and disease, including issues that are
difficult to quantify (e.g. implementation issues or accept-
ability of a vaccine).
3.4.3 Key Parameters that Should be Varied
in Uncertainty Analyses
The experts made clear that parameter uncertainty should
be considered in PSA (see Table 3; Sect. 3.3.9). Addi-
tionally, the experts recommended including the variation
of age and risk group, vaccination schedule, herd protec-
tion, booster or catch-up vaccination, delivery strategy and
vaccination coverage in scenario/uncertainty analyses.
3.4.4 Vaccination-Specific Aspects of Reporting Results
Experts listed aspects that are essential to be reported in
HEEs:
• Discounted and also undiscounted results should be
presented.
• Cumulative results should be reported at various time
points over a model’s construed decision horizon,
including a longitudinal view up to the end of the
defined time horizon of the model.
• Results from various relevant perspectives.
• Cost-effectiveness acceptability curves (CEACs).
• Best- and worst-case scenarios.
• Absolute values and ICERs for all disease-specific
outcomes.
• A report of an HEE should describe the validation/cal-
ibration process, the strength of evidence behind the
input data, and should discuss the potential variation of
results in uncertainty analyses.
• The most recent questionnaire [71] assessing the
credibility of a modelling study needs at least one
infectious disease-specific addition: ‘‘If applicable, why
was a dynamic model not used?’’
4 Summary
As described in the Introduction, the aim of this paper was
to provide a consensus framework on how to apply HEEs
to vaccines and to identify areas where further work is
needed to reach harmonization. The manuscript provides a
comprehensive overview on many important aspects rela-
ted to the economic evaluation of vaccines.
Experts from the field of modelling, health economics,
and immunization decision making discussed 17 vaccine-
specific aspects and reached consensus between modellers
and decision-makers. Steered by a systematic literature
review and expert opinion, this framework suggests the
following:
• In general, international standards as laid down in
established guidelines should be applied and adopted to
specific problems where necessary.
• HEEs on vaccines and vaccination programmes should
be considered by decision-making bodies such as
NITAGs when considering inclusion of a new vaccine
into the national programme to avoid inferior allocation
of resources.
• A mechanical use of a threshold without considering
other criteria may not be necessary. However, infor-
mation about incremental costs and incremental out-
comes of relevant vaccination strategies and ICERs
(with adequate comparator(s)) should be delivered to
decision-making bodies.
• Other interventions (e.g. drugs in preventive medicine)
often share similar characteristics as vaccines. Vaccines
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should only be treated differently where they really are
different (e.g. indirect effects).
• HEEs must be objective, systematic and transparent.
• HEEs should be as complex as necessary but as simple
as possible.
• Ideally, infectious disease models should be dynamic.
• Models should focus on patient-relevant clinical end-
points wherever possible. But surrogates may be used if
no clinical endpoints are available, preferably if they
are validated. Both relying on surrogates and disre-
garding them is risky. The uncertainty concerning
surrogates should be made clear to decision-makers.
• Future costs and outcomes should be discounted. There
are arguments for differential and over time decreasing
discounting (not only for vaccines).
• Information about costs and outcomes from the societal
perspective is relevant. This perspective should ideally
be reported in addition to the payer perspective.
• A broad set of utility-generating characteristics (such as
carer quality of life, utility in anticipation) may be
adequate. However, more research is needed.
• All uncertainties should be accounted for. Uncertainty
analysis plays an important role.
• Methodological problems need to be solved. However,
it is not necessary to reject HEE per se because of the
methodological challenges.
• Funders and decision-makers should recognize that
HEEs (of vaccines) demand time and resources.
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